Regeneron completes purchase of sanofi's stake in libtayo® (cemiplimab)

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions tarrytown, n.y. , july 1, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that it has completed the acquisition of sanofi's stake in libtayo® (cemiplimab), providing regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in regeneron's laboratories.
REGN Ratings Summary
REGN Quant Ranking